{"id":{"repo_id":"rosario","oai_identifier":"oai:repository.urosario.edu.co:10336/18872"},"canonical_url":"https://search.dev.ndltd.org/etd/rosario/oai:repository.urosario.edu.co:10336/18872","repository":{"repo_id":"rosario","name":"Universidad del Rosario","base_url":"https://repository.urosario.edu.co/oai/request"},"display":{"title":"Prevalencia de hiperglicemia perioperatoria y desenlaces en pacientes sometidos a trasplante hepático adulto","abstract":"INTRODUCCIÓN: La hiperglicemia perioperatoria en pacientes sometidos a trasplante hepático no ha sido evaluada en términos de riesgo en la población colombiana sometida a trasplante hepático y en la literatura mundial la evidencia es escasa y controvertida sin embargo los efectos observados son de relevancia clínica en el pacientes trasplantado. OBJETIVO: Determinar si existe asociación de riesgo con mortalidad, infección, NODAT y rechazo del injerto en los pacientes sometidos a trasplante hepático que presentan hiperglicemia en los años 2006-2017 en la FCI – IC. METODOLOGIA: Estudio observacional con componente analítico de cohorte histórica. Se dividieron dos cohortes que se denominaron Grupo 1 y Grupo 2 según si presentaron o no hiperglicemia perioperatoria respectivamente. Se realizó un análisis univariado y bivariado para descripción de la población y posteriormente un modelo de regresión logística de nuestra variable de agrupación con cada uno de los desenlaces primarios y secundarios. RESULTADOS: Se obtuvo el análisis sobre una población diana de 353 pacientes, la prevalencia observada de hiperglicemia perioperatoria fue de 41.6%, principalmente en pacientes no diabéticos. Con respecto a los desenlaces primarios y secundarios no se observó asociación independiente en cada uno de los modelos construidos, sin embargo se observó que la hiperglicemia durante las primeras 48 horas de manejo en UCI aumenta significativamente más el riesgo de NODAT. CONCLUSIONES: Los resultados demuestran que la hiperglicemia perioperatoria más que una causa es un efecto fisiopatológico y que el adecuado control metabólico atenúa los efectos de riesgo que han sido descritos en la literatura.","abstract_html":"INTRODUCCIÓN: La hiperglicemia perioperatoria en pacientes sometidos a trasplante hepático no ha sido evaluada en términos de riesgo en la población colombiana sometida a trasplante hepático y en la literatura mundial la evidencia es escasa y controvertida sin embargo los efectos observados son de relevancia clínica en el pacientes trasplantado. OBJETIVO: Determinar si existe asociación de riesgo con mortalidad, infección, NODAT y rechazo del injerto en los pacientes sometidos a trasplante hepático que presentan hiperglicemia en los años 2006-2017 en la FCI – IC. METODOLOGIA: Estudio observacional con componente analítico de cohorte histórica. Se dividieron dos cohortes que se denominaron Grupo 1 y Grupo 2 según si presentaron o no hiperglicemia perioperatoria respectivamente. Se realizó un análisis univariado y bivariado para descripción de la población y posteriormente un modelo de regresión logística de nuestra variable de agrupación con cada uno de los desenlaces primarios y secundarios. RESULTADOS: Se obtuvo el análisis sobre una población diana de 353 pacientes, la prevalencia observada de hiperglicemia perioperatoria fue de 41.6%, principalmente en pacientes no diabéticos. Con respecto a los desenlaces primarios y secundarios no se observó asociación independiente en cada uno de los modelos construidos, sin embargo se observó que la hiperglicemia durante las primeras 48 horas de manejo en UCI aumenta significativamente más el riesgo de NODAT. CONCLUSIONES: Los resultados demuestran que la hiperglicemia perioperatoria más que una causa es un efecto fisiopatológico y que el adecuado control metabólico atenúa los efectos de riesgo que han sido descritos en la literatura.","abstract_has_math":false,"creators":["Escobar Rubio, Maria Claudia"],"institution":"Universidad del Rosario","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-12-05","date_published":"2018-12-05","updated_at":"2026-07-27T20:46:23Z","subjects":["Hiperglicemia perioperatoria","Trasplante hepático","NODAT","Infección postrasplante","Varias ramas de la medicina, Cirugía","Trasplantes de hígado","Infección de heridas quirúrgicas"],"languages":["spa"],"rights":["info:eu-repo/semantics/openAccess"],"rights_urls":["http://creativecommons.org/licenses/by-nc-nd/2.5/co/"],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["http://repository.urosario.edu.co/handle/10336/18872"],"render_values":[{"text":"http://repository.urosario.edu.co/handle/10336/18872","href":"http://repository.urosario.edu.co/handle/10336/18872","code":true}]}]},"links":{"outbound_url":"https://doi.org/10.48713/10336_18872","outbound_label":"DOI","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Escobar Rubio, Maria Claudia"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-12-05","2019-01-11T22:10:18Z"]},{"key":"dc:publisher","label":"Institution","values":["Universidad del Rosario","Facultad de Medicina","Especialización en Anestesiología FCI"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/masterThesis","info:eu-repo/semantics/acceptedVersion"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Hiperglicemia perioperatoria","Trasplante hepático","NODAT","Infección postrasplante","Varias ramas de la medicina, Cirugía","Trasplantes de hígado","Infección de heridas quirúrgicas"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["spa"]},{"key":"dc:rights","label":"Dc Rights","values":["info:eu-repo/semantics/openAccess","http://creativecommons.org/licenses/by-nc-nd/2.5/co/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://doi.org/10.48713/10336_18872","http://repository.urosario.edu.co/handle/10336/18872"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["INTRODUCCIÓN: La hiperglicemia perioperatoria en pacientes sometidos a trasplante hepático no ha sido evaluada en términos de riesgo en la población colombiana sometida a trasplante hepático y en la literatura mundial la evidencia es escasa y controvertida sin embargo los efectos observados son de relevancia clínica en el pacientes trasplantado. OBJETIVO: Determinar si existe asociación de riesgo con mortalidad, infección, NODAT y rechazo del injerto en los pacientes sometidos a trasplante hepático que presentan hiperglicemia en los años 2006-2017 en la FCI – IC. METODOLOGIA: Estudio observacional con componente analítico de cohorte histórica. Se dividieron dos cohortes que se denominaron Grupo 1 y Grupo 2 según si presentaron o no hiperglicemia perioperatoria respectivamente. Se realizó un análisis univariado y bivariado para descripción de la población y posteriormente un modelo de regresión logística de nuestra variable de agrupación con cada uno de los desenlaces primarios y secundarios. RESULTADOS: Se obtuvo el análisis sobre una población diana de 353 pacientes, la prevalencia observada de hiperglicemia perioperatoria fue de 41.6%, principalmente en pacientes no diabéticos. Con respecto a los desenlaces primarios y secundarios no se observó asociación independiente en cada uno de los modelos construidos, sin embargo se observó que la hiperglicemia durante las primeras 48 horas de manejo en UCI aumenta significativamente más el riesgo de NODAT. CONCLUSIONES: Los resultados demuestran que la hiperglicemia perioperatoria más que una causa es un efecto fisiopatológico y que el adecuado control metabólico atenúa los efectos de riesgo que han sido descritos en la literatura.","2020-01-12 01:01:01: Script de automatizacion de embargos. info:eu-repo/date/embargoEnd/2020-01-11"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:source","label":"Dc Source","values":["Manuscript A. NIH Public Access. 2014;257(1):8–14","Trial C, Umpierrez G, Cardona S, Pasquel F, Jacobs S, Peng L, et al. Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery : GLUCO-. 2015;38(September):1665–72","Manuscript A. NIH Public Access. 2011;373(9677):1798–807","Haven W, Perkal D. Long-term Glycemic Control and Postoperative Infectious Complications. 2015;141","Ammori JB, Sigakis M, Englesbe MJ, O’Reilly M, Pelletier SJ. Effect of Intraoperative Hyperglycemia During Liver Transplantation. J Surg Res. 2007;140(2):227–33","Blasi A, Beltran J, Martin N, Martinez-Pallí G, Lozano JJ, Balust J, et al. Transient hyperglycemia during liver transplantation does not affect the early graft function. Ann Hepatol. 2015;14(5):675–87","Builes-Montaño CE, Montoya-Escobar JF, et al. Complications associated with hyperglicemia in liver transplant patients. Rev. Gastroenterol Mex. 2014 Jul-Sep:79(3): 180-5","Marvin MR, Morton V. Glycemic control and organ transplantation. J Diabetes Sci Technol. 2009;3(6):1365–72","Kömürcü Ö, Fırat AC, Kaplan Ş, Torgay A, Pirat A, Haberal M, et al. Postoperative effects of intraoperative hyperglycemia in liver transplant patients. Exp Clin Transplant. 2015;13:335–9.","Manuscript A, Hyperglycemia P, With AP, Diabetes W. NIH Public Access. 2015;261(5):97–103.","Endoza JOSEM. Prevalence and Clinical Outcome of Hyperglycemia in the Perioperative Period in Noncardiac Surgery. 2010;33(8).","Utility of HbA 1c Levels for Diabetes Case Finding in Hospitalized Patients 54 With. 2002;(December 2001)","Bloom RD, Crutchlow MF. Transplant-associated hyperglycemia. Transplant Rev. 2008;22(1):39–51","Joshi GP, Chung F, Vann MA, Ahmad S, Gan TJ, Goulson DT, et al. Society for Ambulatory Anesthesia Consensus. 2010;111(6):1378–87","Moghissi ES, Korytkowski MT. AACE / ADA Consensus Statement American Association of Clinical Endocrinologists And American Diabetes Association CONSENSUS STATEMENT ON INPATIENT GLYCEMIC CONTROL. 2009","Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P. Clinical Guideline Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients : A Clinical Practice Guideline From the American College of Physicians. 2011;(November 2010).","Jacobi J, Bircher N, Krinsley J, Agus M, Braithwaite SS, Deutschman C, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. 2012;40(12):3251–76","Lazar HL, Mcdonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR, et al. The Society of Thoracic Surgeons Practice Guideline Series : Blood Glucose Management During Adult Cardiac Surgery. ATS. 2009;87(2):663–9.","Manuscript A. NIH Public Access. 2013;1–16","Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans Role of Oxidative Stress. 2002;2067–73.","Chan TM. The Permissive Effects of Glucocorticoid on Hepatic Gluconeogenesis. 1984;(12):7426–32.","Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Rapid Publication Mechanism of Free Fatty Acid – induced Insulin Resistance in Humans. 1996;97(12):2859–","Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor a inhibits signaling from the insulin receptor. 1994;91(May):4854–8","Thorell A1, Efendic S, Gutniak M, Häggmark T LO. Insulin resistance after abdominal surgery. Br J Surg. 1994;Jan;81(1):59–63","RS. C. The hyperglycaemic response to different types of surgery and anaesthesia. Br J Anaesth. 1970;Jan;42(1):45–53","Rehman H, Mohammed K. Perioperative Management of. 2003;607–11","Park CS. Predictive roles of intraoperative blood glucose for posttransplant outcomes in liver transplantation. World J Gastroenterol. 2015;21(22):6835–41","García-Compean D1, Jaquez-Quintana JO M-GH. Hepatogenous diabetes. Current views of an ancient problem. Ann Hepatol. 2009;8(1):13–20","Infection HCV. Hepatitis C Virus Infection and Diabetes : Direct Involvement of the Virus in the Development of Insulin Resistance. 2004;840–8.","Shangraw RE, Hexem JG. Glucose and potassium metabolic responses to insulin during liver transplantation. Liver Transpl Surg. 1996;2(6):443– 54.","Park C, Hsu C, Neelakanta G, Nourmand H, Braunfeld M, Wray C, et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. Transplantation. 2009;87(7):1031–6.","Wallia A, Schmidt K, Johnson Oakes D, Pollack T, Welsh N, Kling-Colson S, et al. Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. J Clin Endocrinol Metab. 2016;102(November 2016):jc.2016-3279","Wallia A, Parikh ND, Molitch ME, Mahler E, Tian L, Huang JJ, et al. Posttransplant hyperglycemia is associated with increased risk of liver 56 allograft rejection. Transplantation. 2010;89(2):222–6.","Chung HS, Lee S, Kwon SJ, Park CS. Perioperative predictors for refractory hyperglycemia during the neohepatic phase of liver transplantation. Transplant Proc 2014;46(10):3474–80","Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002; 87(3):978–982","Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med.2001; 345(19):1359– 1367.","Infer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo, R, Cook D, Dodek P, Henderson WR, H´ebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360(13):1283–1297.","Moghissi ES, KorytkowskiMT, DiNardoM, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE; American Association of Clinical Endocrinologists; AmericanDiabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009; 32(6):1119–1131","Thomas MC, Moran J, Mathew TH, Russ GR, Rao MM. Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes. BMC Nephrol. 2000; 1:1.","Thomas MC, Mathew TH, Russ GR, Rao MM, Moran J. Early perioperative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001; 72(7): 1321–1324","Ganji MR, Charkhchian M, Hakemi M, Nederi GH, Solymanian T, Saddadi F, Amini M, Najafi I. Association of hyperglycemia on allograft function in the early period after renal transplantation.Transplant Proc. 2007;39(4):852–854","Ammori JB, Sigakis M, Englesbe MJ, O’Reilly M, Pelletier SJ. Effect of intraoperative hyperglycemia during liver transplantation. J. Surg. Res. 140(2), 227–233 (2007).","Özgür Kömürcü et al. Experimental and Clinical Transplantation (2015) Suppl 1: 335-339","Werner KT, Mackey PA, Castro JC. Hyperglycemia during the immediate period following liver transplantation. 2016 Jan 27; 2(1):FSO97","Amisha Wallia, Kathleen Schmidt, Diana Johnson, et al. Glycemic Control Reduces Infections in Post–Liver Transplant Patients: Results of a Prospective, Randomized Study","instname:Universidad del Rosario","reponame:Repositorio Institucional EdocUR"]},{"key":"dc:title","label":"Title","values":["Prevalencia de hiperglicemia perioperatoria y desenlaces en pacientes sometidos a trasplante hepático adulto"]}]}],"canonical_facts":{"dc:creator":["Escobar Rubio, Maria Claudia"],"dc:date":["2018-12-05","2019-01-11T22:10:18Z"],"dc:description":["INTRODUCCIÓN: La hiperglicemia perioperatoria en pacientes sometidos a trasplante hepático no ha sido evaluada en términos de riesgo en la población colombiana sometida a trasplante hepático y en la literatura mundial la evidencia es escasa y controvertida sin embargo los efectos observados son de relevancia clínica en el pacientes trasplantado. OBJETIVO: Determinar si existe asociación de riesgo con mortalidad, infección, NODAT y rechazo del injerto en los pacientes sometidos a trasplante hepático que presentan hiperglicemia en los años 2006-2017 en la FCI – IC. METODOLOGIA: Estudio observacional con componente analítico de cohorte histórica. Se dividieron dos cohortes que se denominaron Grupo 1 y Grupo 2 según si presentaron o no hiperglicemia perioperatoria respectivamente. Se realizó un análisis univariado y bivariado para descripción de la población y posteriormente un modelo de regresión logística de nuestra variable de agrupación con cada uno de los desenlaces primarios y secundarios. RESULTADOS: Se obtuvo el análisis sobre una población diana de 353 pacientes, la prevalencia observada de hiperglicemia perioperatoria fue de 41.6%, principalmente en pacientes no diabéticos. Con respecto a los desenlaces primarios y secundarios no se observó asociación independiente en cada uno de los modelos construidos, sin embargo se observó que la hiperglicemia durante las primeras 48 horas de manejo en UCI aumenta significativamente más el riesgo de NODAT. CONCLUSIONES: Los resultados demuestran que la hiperglicemia perioperatoria más que una causa es un efecto fisiopatológico y que el adecuado control metabólico atenúa los efectos de riesgo que han sido descritos en la literatura.","2020-01-12 01:01:01: Script de automatizacion de embargos. info:eu-repo/date/embargoEnd/2020-01-11"],"dc:format":["application/pdf"],"dc:identifier":["https://doi.org/10.48713/10336_18872","http://repository.urosario.edu.co/handle/10336/18872"],"dc:language":["spa"],"dc:publisher":["Universidad del Rosario","Facultad de Medicina","Especialización en Anestesiología FCI"],"dc:rights":["info:eu-repo/semantics/openAccess","http://creativecommons.org/licenses/by-nc-nd/2.5/co/"],"dc:source":["Manuscript A. NIH Public Access. 2014;257(1):8–14","Trial C, Umpierrez G, Cardona S, Pasquel F, Jacobs S, Peng L, et al. Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery : GLUCO-. 2015;38(September):1665–72","Manuscript A. NIH Public Access. 2011;373(9677):1798–807","Haven W, Perkal D. Long-term Glycemic Control and Postoperative Infectious Complications. 2015;141","Ammori JB, Sigakis M, Englesbe MJ, O’Reilly M, Pelletier SJ. Effect of Intraoperative Hyperglycemia During Liver Transplantation. J Surg Res. 2007;140(2):227–33","Blasi A, Beltran J, Martin N, Martinez-Pallí G, Lozano JJ, Balust J, et al. Transient hyperglycemia during liver transplantation does not affect the early graft function. Ann Hepatol. 2015;14(5):675–87","Builes-Montaño CE, Montoya-Escobar JF, et al. Complications associated with hyperglicemia in liver transplant patients. Rev. Gastroenterol Mex. 2014 Jul-Sep:79(3): 180-5","Marvin MR, Morton V. Glycemic control and organ transplantation. J Diabetes Sci Technol. 2009;3(6):1365–72","Kömürcü Ö, Fırat AC, Kaplan Ş, Torgay A, Pirat A, Haberal M, et al. Postoperative effects of intraoperative hyperglycemia in liver transplant patients. Exp Clin Transplant. 2015;13:335–9.","Manuscript A, Hyperglycemia P, With AP, Diabetes W. NIH Public Access. 2015;261(5):97–103.","Endoza JOSEM. Prevalence and Clinical Outcome of Hyperglycemia in the Perioperative Period in Noncardiac Surgery. 2010;33(8).","Utility of HbA 1c Levels for Diabetes Case Finding in Hospitalized Patients 54 With. 2002;(December 2001)","Bloom RD, Crutchlow MF. Transplant-associated hyperglycemia. Transplant Rev. 2008;22(1):39–51","Joshi GP, Chung F, Vann MA, Ahmad S, Gan TJ, Goulson DT, et al. Society for Ambulatory Anesthesia Consensus. 2010;111(6):1378–87","Moghissi ES, Korytkowski MT. AACE / ADA Consensus Statement American Association of Clinical Endocrinologists And American Diabetes Association CONSENSUS STATEMENT ON INPATIENT GLYCEMIC CONTROL. 2009","Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P. Clinical Guideline Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients : A Clinical Practice Guideline From the American College of Physicians. 2011;(November 2010).","Jacobi J, Bircher N, Krinsley J, Agus M, Braithwaite SS, Deutschman C, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. 2012;40(12):3251–76","Lazar HL, Mcdonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR, et al. The Society of Thoracic Surgeons Practice Guideline Series : Blood Glucose Management During Adult Cardiac Surgery. ATS. 2009;87(2):663–9.","Manuscript A. NIH Public Access. 2013;1–16","Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans Role of Oxidative Stress. 2002;2067–73.","Chan TM. The Permissive Effects of Glucocorticoid on Hepatic Gluconeogenesis. 1984;(12):7426–32.","Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Rapid Publication Mechanism of Free Fatty Acid – induced Insulin Resistance in Humans. 1996;97(12):2859–","Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor a inhibits signaling from the insulin receptor. 1994;91(May):4854–8","Thorell A1, Efendic S, Gutniak M, Häggmark T LO. Insulin resistance after abdominal surgery. Br J Surg. 1994;Jan;81(1):59–63","RS. C. The hyperglycaemic response to different types of surgery and anaesthesia. Br J Anaesth. 1970;Jan;42(1):45–53","Rehman H, Mohammed K. Perioperative Management of. 2003;607–11","Park CS. Predictive roles of intraoperative blood glucose for posttransplant outcomes in liver transplantation. World J Gastroenterol. 2015;21(22):6835–41","García-Compean D1, Jaquez-Quintana JO M-GH. Hepatogenous diabetes. Current views of an ancient problem. Ann Hepatol. 2009;8(1):13–20","Infection HCV. Hepatitis C Virus Infection and Diabetes : Direct Involvement of the Virus in the Development of Insulin Resistance. 2004;840–8.","Shangraw RE, Hexem JG. Glucose and potassium metabolic responses to insulin during liver transplantation. Liver Transpl Surg. 1996;2(6):443– 54.","Park C, Hsu C, Neelakanta G, Nourmand H, Braunfeld M, Wray C, et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. Transplantation. 2009;87(7):1031–6.","Wallia A, Schmidt K, Johnson Oakes D, Pollack T, Welsh N, Kling-Colson S, et al. Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. J Clin Endocrinol Metab. 2016;102(November 2016):jc.2016-3279","Wallia A, Parikh ND, Molitch ME, Mahler E, Tian L, Huang JJ, et al. Posttransplant hyperglycemia is associated with increased risk of liver 56 allograft rejection. Transplantation. 2010;89(2):222–6.","Chung HS, Lee S, Kwon SJ, Park CS. Perioperative predictors for refractory hyperglycemia during the neohepatic phase of liver transplantation. Transplant Proc 2014;46(10):3474–80","Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002; 87(3):978–982","Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med.2001; 345(19):1359– 1367.","Infer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo, R, Cook D, Dodek P, Henderson WR, H´ebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360(13):1283–1297.","Moghissi ES, KorytkowskiMT, DiNardoM, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE; American Association of Clinical Endocrinologists; AmericanDiabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009; 32(6):1119–1131","Thomas MC, Moran J, Mathew TH, Russ GR, Rao MM. Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes. BMC Nephrol. 2000; 1:1.","Thomas MC, Mathew TH, Russ GR, Rao MM, Moran J. Early perioperative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001; 72(7): 1321–1324","Ganji MR, Charkhchian M, Hakemi M, Nederi GH, Solymanian T, Saddadi F, Amini M, Najafi I. Association of hyperglycemia on allograft function in the early period after renal transplantation.Transplant Proc. 2007;39(4):852–854","Ammori JB, Sigakis M, Englesbe MJ, O’Reilly M, Pelletier SJ. Effect of intraoperative hyperglycemia during liver transplantation. J. Surg. Res. 140(2), 227–233 (2007).","Özgür Kömürcü et al. Experimental and Clinical Transplantation (2015) Suppl 1: 335-339","Werner KT, Mackey PA, Castro JC. Hyperglycemia during the immediate period following liver transplantation. 2016 Jan 27; 2(1):FSO97","Amisha Wallia, Kathleen Schmidt, Diana Johnson, et al. Glycemic Control Reduces Infections in Post–Liver Transplant Patients: Results of a Prospective, Randomized Study","instname:Universidad del Rosario","reponame:Repositorio Institucional EdocUR"],"dc:subject":["Hiperglicemia perioperatoria","Trasplante hepático","NODAT","Infección postrasplante","Varias ramas de la medicina, Cirugía","Trasplantes de hígado","Infección de heridas quirúrgicas"],"dc:title":["Prevalencia de hiperglicemia perioperatoria y desenlaces en pacientes sometidos a trasplante hepático adulto"],"dc:type":["info:eu-repo/semantics/masterThesis","info:eu-repo/semantics/acceptedVersion"]},"updated_at":"2026-07-27T20:46:23Z"}